EUVIMEDEUVIMED entdecken
Kommentar

Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions

Samantha Anderer

JAMA · 19.05.2026 · 335 (19) · 1656

DOI: 10.1001/jama.2026.2123 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA, erschienen am 19.05.2026. Verfasst von Samantha Anderer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Anderer, S. (2026). Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions. JAMA, 335(19), 1656. https://doi.org/10.1001/jama.2026.2123

Vancouver

Anderer S. Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions. JAMA. 2026;335(19):1656. doi:10.1001/jama.2026.2123

BibTeX
@article{Anderer2026,
  author = {Anderer, Samantha},
  title = {Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {19},
  pages = {1656},
  doi = {10.1001/jama.2026.2123}
}
Kostenlos starten →